Cryo-Cell International Inc (CCEL)
8.15
+0.35
(+4.49%)
USD |
NYAM |
Apr 26, 16:00
8.15
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 66.05M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 87.95% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.157 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -1.019 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 76.33% |
Profile
| Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment. |
| URL | https://www.cryo-cell.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jul. 12, 2024 (est.) |
| Last Earnings Release | Apr. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 01, 2022 |
Ratings
Profile
| Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment. |
| URL | https://www.cryo-cell.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jul. 12, 2024 (est.) |
| Last Earnings Release | Apr. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 01, 2022 |